Overview


According to FutureWise analysis the market for latam hypoactive sexual desire disorder (hsdd) treatment in 2023 is US$ 0.15 billion, and is expected to reach US$ 0.21 billion by 2031 at a CAGR of 4.02%.

Hyposexual desire complaint (HSDD) in women is defined as insufficiency or lack of sexual fantasies and desire of sexual exertion. Likewise, HSDD is a largely current sexual desire complaint in women, which can oppressively impact the quality of life of a case. Therefore, treatment is needed, which involves use of certain medicines similar as bupropion, buspirone, bremelanotide, and flibanserin. These medicines have varying medium of action on HSDD. For case, the FDA approved treatment bremelanotide works by lowering serotonin situations in brain and adding norepinephrine and dopamine neurotransmitters. Likewise, women hypoactive sexual desire complaint treatments are available in hospitals, conventions, and through online retailers. The factors that contribute to LATAM women hypoactive sexual desire complaint treatment request growth include rise in frequence of life affections, similar as stress, depression, anxiety, and dragged fatigue, and rise in use of drugs, which induces state of hypoactive sexual desire complaint. For case, stress can lead to release of hormones similar as cortisol and epinephrine. These hormones in high situations can lead to lowered coitus drive. Also, depression is marked by depressed mood, dropped energy, and loss of interest in enjoyable conditioning. In addition, rise in number of surgical procedures, which lead to sexual dysfunction, are anticipated to boost LATAM women hypoactive sexual desire complaint treatment request growth during the cast period. Still, warrant in mindfulness related to hypoactive sexual desire complaint are anticipated to hinder the request growth during the cast period. For case, there's a lack of public education on sexual health issues in numerous countries of Latin America similar as Brazil and Guyana. This contributes to low opinion of HSDD in these countries. Also, presence of strong channel products, which are in their late phases of clinical trials are anticipated to get approved for commercialization in coming times. Hence, presence of channel medicines offer a economic occasion for the LATAM women hypoactive sexual desire complaint treatment request.

FutureWise Market Research has instantiated a report that provides an intricate analysis of LATAM Hypoactive Sexual Desire Disorder (HSDD) Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the LATAM Hypoactive Sexual Desire Disorder (HSDD) Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • AUROBINDO PHARMA
  • BRISTOL-MYERS SQUIBB COMPANY
  • GLAXOSMITHKLINE PLC (GSK)
  • MYLAN N.V.
  • NOVARTIS INTERNATIONAL AG
  • PALATIN TECHNOLOGIES, INC.
  • SPROUT PHARMACEUTICALS, INC.
  • SUN PHARMACEUTICAL INDUSTRIES LIMITED
  • TEVA PHARMACEUTICAL INDUSTRIES LTD. (ACTAVIS GENERICS)
  • ZYDUS CADILA

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Treatment Type

  • Buspirone
  • Bupropion

By Sales Channel

  • Hospitals
  • Clinics
  • Online Retailers

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the LATAM Hypoactive Sexual Desire Disorder (HSDD) Treatment Market By Treatment Type, By Sales Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   LATAM Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of LATAM Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   LATAM Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   LATAM Hypoactive Sexual Desire Disorder (HSDD) Treatment Market, By Treatment Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Buspirone
        2. Bupropion

  • 8.   LATAM Hypoactive Sexual Desire Disorder (HSDD) Treatment Market, By Sales Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Clinics
        3. Online Retailers

  • 9.   North America LATAM Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America LATAM Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe LATAM Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific LATAM Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. AUROBINDO PHARMA
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. BRISTOL-MYERS SQUIBB COMPANY
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. GLAXOSMITHKLINE PLC (GSK)
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. MYLAN N.V.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. NOVARTIS INTERNATIONAL AG
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. PALATIN TECHNOLOGIES, INC.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. SPROUT PHARMACEUTICALS, INC.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. SUN PHARMACEUTICAL INDUSTRIES LIMITED
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. TEVA PHARMACEUTICAL INDUSTRIES LTD. (ACTAVIS GENERICS)
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. ZYDUS CADILA
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients